Navigation Links
MicroRNAs may be key to HIV's ability to hide, evade drugs, Jefferson scientists find
Date:9/30/2007

(PHILADELPHIA) Tiny pieces of genetic material called microRNA (miRNA), better known for its roles in cancer, could be a key to unlocking the secrets of how HIV, the AIDS virus, evades detection, hiding in the immune system. Researchers at Jefferson Medical College in Philadelphia have shown that when an individual infected with HIV receives a powerful cocktail of antiviral agents called HAART (highly active antiretroviral therapy), the virus calls on miRNAs to help it remain quiet and practically undetectable, temporarily shutting down its ability to replicate and infect.

The work, which appears September 30, 2007 in an early online edition of the journal Nature Medicine, may also have implications for new treatment strategies against the virus. According to Hui Zhang, M.D., Ph.D., associate professor of Medicine in the Division of Infectious Diseases at Jefferson Medical College of Thomas Jefferson University, who led the work, if researchers can learn to manipulate miRNAs inhibitory effect on HIV, they might be able to devise strategies to bring the virus out of hiding, or latency, making it vulnerable to drugs and the bodys immune system.

While HAART can drive the number of HIV particles in the blood to practically undetectable levels, the virus is not eliminated. It hides in resting immune system CD4 T cells in the body, including the testis, brain, and other places. The drug combination has to be taken the rest of the patients life; if halted, the virus becomes active again.

HIV latency and how to eliminate the replication-competent and hidden virus are big problems, Dr. Zhang explains, noting that the molecular mechanisms that are responsible for latency are unclear.

Dr. Zhang, post-doctoral fellow Jialing Huang, Ph.D., and their colleagues may have come across one possible explanation. HIV, they have found, recruits cellular miRNA noncoding genetic material that has been shown to play a variety of roles in cancer and in biological regulation in resting T cells to control the translation of viral RNA into protein. This is the last step in the creation of HIV antigens, which make the virus visible to the immune system.

The team showed that a cluster of miRNAs bind to a certain location on the viral RNA, which in turn, blocks the creation of important proteins, and HIV replication. Resting CD4 T cells, they found, are enriched with more than the normal amount of these miRNAs compared to the activated T cells. When the researchers used antisense technology to block miRNA-caused viral inhibition, they found that the HIV again was active and able to replicate proving miRNAs critical role in maintaining latency.

While Dr. Zhang and his team continue to study how cellular miRNA contributes to latency, he notes that using miRNA inhibitors might become a kind of therapeutic approach to get the virus out of hiding, making it visible and a target for the immune system. Thats the next step, he says.


'/>"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Role Of MicroRNAs In Angiogenesis Researched
2. MicroRNAs Can Be Tumor Suppressors
3. Mexico and US border attain a new outlook due to BiNational Sustainability Laboratory
4. Alcoholics are prone to disability
5. Hypertension drugs could lower Disability
6. Running delays disability in the aged
7. Restricted Activity Predicts Disability
8. Adding contrast improves ultrasounds ability to detect prostate cancer
9. CoQ10 bioavailability increased by Nanotechnology
10. Amputation may depend on availability of vascular surgeons
11. The growing availability of Fake drugs in the market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... Springs, FL (PRWEB) , ... February 13, 2016 , ... ... the environmental impact of American businesses. , The increasingly modern world of instantaneous ... more often on non-renewable energy sources such as oil and coal, which pollutes our ...
(Date:2/13/2016)... ... 2016 , ... DDi , a Makro company, makes ... its expertise in eClinical Solutions. DDi has built its solution competency with a ... global clients. DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on Monday, February 8, ...
(Date:2/12/2016)... ... 12, 2016 , ... Coco Libre, the maker of coconut water beverages with ... Style Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature Organic ... The invitation-only gifting suite, held this year at the W Hollywood Hotel, has become ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman and ... J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, VA ... Southern Nevada Healthcare System. This will be the first Fisher House in Nevada, ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Affairs leaders at pharmaceutical organizations are looking to either start or ... some companies have conducted a significant number of clinical trials in ... as India and China ... India are now requiring local clinical trials to win ... China and India are ...
(Date:2/12/2016)... , Feb. 12, 2016  Innophos Holdings, Inc. (NASDAQ: ... specialty ingredients, today announced that it will host a live ... ET to discuss its fourth quarter and full year 2015 ... The press release detailing fourth quarter and full year results ... close. --> --> ...
(Date:2/12/2016)... VIEJO , Kalifornien, 12. Februar 2016 /PRNewswire/ ... mit der Aufnahme von Patienten für eine Studie ... von Aneurysmen („WEB") speziell für die Behandlung von ... Spelle , MD, Leiter der Neuroradiologie an der ... Frankreich, und Hauptprüfarzt der CLARYS-Studie hat den ersten ...
Breaking Medicine Technology: